logo-loader

'Interest is growing exponentially', says Oxford Biodynamics' Christian Hoyer Millar

Last updated: 14:02 23 Mar 2017 GMT, First published: 10:02 23 Mar 2017 GMT

Oxford Biodynamics (LON:OBD) CEO Christian Hoyer Millar and CSO Sasha Akoulitchev talk to Proactive's Andrew Scott about the company's platform EpiSwitch as well as the overall strategy and outlook.

Their technology manages biomarkers in people’s blood to help pharmaceutical companies identify which patients will react to certain drugs.

''We've worked with six of the biggest pharma and biotech companies in the world so far. We've undertaken about 23 projects and the interest in what we're doing is growing exponentially'', Hoyer Millar says.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

2 hours, 10 minutes ago